Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/01/2873714/0/en/Tarsus-to-Report-First-Quarter-2024-Financial-Results-on-Wednesday-May-8-2024.html
https://www.globenewswire.com/news-release/2024/04/23/2867657/0/en/Tarsus-Strengthens-Financial-Position-and-Refinances-Existing-Debt-with-200-Million-Non-dilutive-Financing-Commitment-from-Pharmakon.html
https://www.globenewswire.com//news-release/2024/03/05/2840930/0/en/Tarsus-to-Participate-at-Upcoming-Investor-Conferences.html
https://www.globenewswire.com//news-release/2024/03/05/2840447/0/en/Tarsus-Introduces-Mite-Party-Campaign-for-XDEMVY-lotilaner-ophthalmic-solution-0-25-to-Educate-Consumers-about-Demodex-Blepharitis.html
https://www.globenewswire.com/news-release/2024/03/01/2838554/0/en/Tarsus-Announces-Pricing-of-100-0-Million-Public-Offering.html
https://www.globenewswire.com//news-release/2024/02/29/2838449/0/en/Tarsus-Announces-Proposed-100-0-Million-Public-Offering.html
https://www.globenewswire.com//news-release/2024/02/27/2835785/0/en/Tarsus-Reports-Strong-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Business-Achievements.html
https://www.globenewswire.com//news-release/2024/02/22/2833632/0/en/Tarsus-Announces-Positive-Topline-Results-from-Carpo-a-Phase-2a-Proof-of-Concept-Tick-Kill-Trial-Evaluating-TP-05-lotilaner-for-the-Prevention-of-Lyme-Disease.html
https://www.globenewswire.com//news-release/2024/02/20/2832343/0/en/Tarsus-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-Tuesday-February-27-2024.html
https://www.globenewswire.com/news-release/2024/01/31/2821594/0/en/Tarsus-to-Participate-in-Fireside-Chat-at-the-Sixth-Annual-Guggenheim-Healthcare-Talks-Conference.html